Document Detail


Administration of prostacyclin prevents ventricular fibrillation following coronary occlusion in conscious dogs.
MedLine Citation:
PMID:  6182407     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The effects of prostacyclin (PGI2) on ventricular arrhythmias following 20 min of coronary occlusion and release were studied in 34 conscious dogs. We administered PGI2 at 100 ng/kg/min and did not observe significant changes in heart rate, blood pressure, or systemic vascular resistance. During the control period, heart rate was 97 +/- 30 (mean +/- SEM) vs. 99 +/- 28 in the PGI2-treated group. Mean arterial pressure was 115 +/- 26 mm Hg and 109 +/- 10 mm Hg in the control and PGI2 groups, respectively. Systemic vascular resistance declined minimally from 2,985 +/- 221 dyn . s . cm-5 to 2,484 +/- 135 dyn . s . cm-5 during the PGI2 infusion (p = NS). Following coronary occlusion, the frequency of ventricular fibrillation was reduced from 53% (9/17) in the control group to 6% (1/17) in the PGI2 group (p less than 0.01). Overall 80-min postinfarction survival was 64% in the group receiving PGI2 infusion compared to 24% in the control group (p less than 0.05). The effects of PGI2 in preventing ventricular fibrillation following acute coronary occlusion can be ascribed to a direct action of this prostaglandin on the myocardium, rather than to an indirect effect due to a reduction in systemic vascular resistance.
Authors:
V A Starnes; R K Primm; R L Woosley; J A Oates; J W Hammon
Related Documents :
434177 - Shunting of microspheres across the canine coronary circulation.
8809167 - Synthesis and selective coronary vasodilatory activity of 3,4-dihydro-2,2-bis(methoxyme...
6661747 - A new apex-ejecting perfused rat heart preparation: relation between coronary flow and ...
2180577 - Comparison of meglumine sodium diatrizoate, iopamidol, and iohexol for coronary angiogr...
1756847 - Inhaled clemastine, an h1 antihistamine inhibits airway narrowing caused by aerosols of...
2066367 - Increased proteoglycan synthesis by the cardiovascular system of coarctation hypertensi...
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  4     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:    1982 Sep-Oct
Date Detail:
Created Date:  1982-12-16     Completed Date:  1982-12-16     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  765-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Blood Pressure / drug effects
Cardiac Output / drug effects
Coronary Disease / complications*,  physiopathology
Dogs
Dose-Response Relationship, Drug
Electrocardiography
Epoprostenol / pharmacology*
Heart Rate / drug effects
Hemodynamics / drug effects
Platelet Aggregation / drug effects
Prostaglandins / pharmacology*
Vascular Resistance / drug effects
Ventricular Fibrillation / prevention & control*
Grant Support
ID/Acronym/Agency:
GM-15431/GM/NIGMS NIH HHS; RR-05424/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Prostaglandins; 35121-78-9/Epoprostenol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pre- and postsynaptic effects of SKF64139, a phenylethanolamine N-methyltransferase inhibitor, in co...
Next Document:  Effect of tiapamil and nifedepine during critical coronary stenosis and in the presence of adrenergi...